Zobrazeno 1 - 10
of 32
pro vyhledávání: ''
Autor:
Arinobu Tojo, Masamichi Isobe, Seiko Kato, Takaaki Konuma, Mai Mizusawa, Kazuaki Yokoyama, Maki Oiwa-Monna, Satoshi Takahashi
Publikováno v:
Leukemialymphoma. 60(9)
Genetic mutation is one of the most powerful prognostic factors for adult patients with acute myeloid leukemia (AML). The FMS-like tyrosine kinase 3 (FLT3) gene mutations, including internal tandem...
Publikováno v:
Leukemialymphoma. 60(5)
Chronic lymphocytic leukemia (CLL) constitutes the largest percentage of adult leukemia cases in Western countries. Classically, fludarabine (Flu) is an effective drug used as a first-line therapy for CLL; however, Flu resistance limits its clinical
Autor:
Tomas Cudrnak, Manuel Saenz-de-Viteri
Publikováno v:
Leukemialymphoma. 60(3)
Ocular side effects associated with cytotoxic chemotherapy are rarely severe or dose limiting but serious toxicity has been associated with molecularly targeted cancer therapies, particularly tyros...
Autor:
Omar S. Aljitawi, Paul Frankel, Edward M. Newman, Mark Kirschbaum, Robert T. Chen, Kenneth K. Chan, Zhiliang Xie, Timothy W. Synold, Leslie Popplewell, Joseph Tuscano, Yun Yen
Publikováno v:
Leukemialymphoma. 57(10)
We performed a phase I study of GTI-2040, an antisense oligonucleotide against ribonucleotide reductase mRNA, on a novel dosing schedule of days 1-4 and 15-18 by continuous infusion to examine efficacy and tolerability in patients with leukemia. A do
Publikováno v:
Leukemialymphoma. 57(7)
One of the severe toxicities of pegaspargase (PEG) is the development of allergic reactions. This study retrospectively assessed 311 PEG doses administered to 139 acute lymphoblastic leukemia patients from May 1, 2008 to July 30, 2014 for allergic re
Autor:
Marylou Cardenas-Turanzas, Elias Jabbour, Farhad Ravandi, Susan O'Brien, Hagop M. Kantarjian, Guillermo Garcia-Manero, Ohad Benjamini, Jorge E. Cortes, Stefan Faderl, Preetesh Jain, Alfonso Quintás-Cardama, Gautam Borthakur, Mary Beth Rios
Publikováno v:
Leukemia & lymphoma, vol 55, iss 12
With improved outcome for patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), treatment discontinuation has become increasingly attractive to patients. We analyzed the outcomes of patients who chose to discont
Autor:
Jeffrey A. Jones, Richard A. Larson, Guido Marcucci, John C. Byrd, Weiqiang Zhao, Thomas S. Lin, Kanti R. Rai, Bercedis Peterson, Nyla A. Heerema, Amy S. Ruppert
Publikováno v:
Leukemialymphoma. 54(12)
Alemtuzumab consolidation has been investigated to improve remission duration after fludarabine-based induction for chronic lymphocytic leukemia (CLL). The impact on genomic high-risk disease remains unknown. Cancer and Leukemia Group B (CALGB) 19901
Autor:
Karen W.L. Yee, Donna E. Hogge, Liang Piu Koh, Keith B. Glaser, Xiaohui Li, Evelyn McKeegan, Wendy Stock, Eunice S. Wang, Dawn M. Carlson, Daniel H. Albert, Sari H. Enschede, Rajendra S. Pradhan, Matthew Dudley
Publikováno v:
Leukemialymphoma. 53(8)
Linifanib, a potent oral inhibitor of fms-like tyrosine kinase 3 (FLT3) and vascular endothelial growth factor receptor tyrosine kinases, has demonstrated promising preclinical single-agent and synergistic anti-leukemic activity in combination with c
Autor:
Anna Panovská, Hana Skuhrová Francová, Karla Plevová, Jiří Mayer, Martin Trbušek, Michael Doubek, Veronika Navrkalová, Jitka Malčíková, Šárka Pospíšilová, Boris Tichý, Marek Mráz, Yvona Brychtová, Jana Lochmanová, Ludmila Šebejová, Petr Kuglík, Jana Šmardová
Publikováno v:
Leukemialymphoma. 53(9)
A poor prognosis in chronic lymphocytic leukemia (CLL) is associated particularly with the presence of del(17p) aff ecting tumor suppressor gene TP53 . Th is deletion is in almost all cases of progressive leukemia accompanied by a mutation in the oth
Publikováno v:
Leukemialymphoma. 53(6)
Treatment of hairy cell leukemia (HCL) with cladribine induces durable remissions. Common toxicities are myelosuppression and immunosuppression with low counts of CD4 + T cells. Skin rash (SR) is seldom described. We collected clinical and laboratory